JP2000510714A - 医療装置用のイオン架橋ポリマー組成物の二次成形 - Google Patents
医療装置用のイオン架橋ポリマー組成物の二次成形Info
- Publication number
- JP2000510714A JP2000510714A JP09538060A JP53806097A JP2000510714A JP 2000510714 A JP2000510714 A JP 2000510714A JP 09538060 A JP09538060 A JP 09538060A JP 53806097 A JP53806097 A JP 53806097A JP 2000510714 A JP2000510714 A JP 2000510714A
- Authority
- JP
- Japan
- Prior art keywords
- ion
- hydrogel
- ions
- medical device
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000465 moulding Methods 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims description 40
- 229920006037 cross link polymer Polymers 0.000 title description 5
- 239000000017 hydrogel Substances 0.000 claims abstract description 91
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 27
- 238000004132 cross linking Methods 0.000 claims abstract description 21
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 14
- 229920000615 alginic acid Polymers 0.000 claims abstract description 14
- 239000001103 potassium chloride Substances 0.000 claims abstract description 13
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052788 barium Inorganic materials 0.000 claims abstract description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229940072056 alginate Drugs 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 67
- 239000000243 solution Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 229920000642 polymer Polymers 0.000 claims description 26
- 239000008151 electrolyte solution Substances 0.000 claims description 20
- 229910001868 water Inorganic materials 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000003431 cross linking reagent Substances 0.000 claims description 17
- 235000002639 sodium chloride Nutrition 0.000 claims description 16
- 125000002091 cationic group Chemical group 0.000 claims description 15
- 229910001422 barium ion Inorganic materials 0.000 claims description 14
- 229910001424 calcium ion Inorganic materials 0.000 claims description 14
- 239000007884 disintegrant Substances 0.000 claims description 14
- 229920001282 polysaccharide Polymers 0.000 claims description 14
- 239000005017 polysaccharide Substances 0.000 claims description 14
- 150000004804 polysaccharides Chemical class 0.000 claims description 14
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 13
- -1 aluminum ion Chemical class 0.000 claims description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 13
- 150000002500 ions Chemical class 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000000783 alginic acid Substances 0.000 claims description 10
- 229960001126 alginic acid Drugs 0.000 claims description 10
- 150000004781 alginic acids Chemical class 0.000 claims description 10
- 230000014759 maintenance of location Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052782 aluminium Inorganic materials 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 8
- 229910001432 tin ion Inorganic materials 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 229920002230 Pectic acid Polymers 0.000 claims description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 claims description 7
- 239000010318 polygalacturonic acid Substances 0.000 claims description 7
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 6
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 6
- 229910001431 copper ion Inorganic materials 0.000 claims description 6
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 5
- 125000000129 anionic group Chemical group 0.000 claims description 5
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 5
- 229910052920 inorganic sulfate Inorganic materials 0.000 claims description 5
- 229910001427 strontium ion Inorganic materials 0.000 claims description 5
- 241001631457 Cannula Species 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims description 4
- 229920002971 Heparan sulfate Polymers 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229910052816 inorganic phosphate Inorganic materials 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 239000003899 bactericide agent Substances 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 229920002567 Chondroitin Polymers 0.000 claims description 2
- 229910001423 beryllium ion Inorganic materials 0.000 claims description 2
- PWOSZCQLSAMRQW-UHFFFAOYSA-N beryllium(2+) Chemical compound [Be+2] PWOSZCQLSAMRQW-UHFFFAOYSA-N 0.000 claims description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 2
- 229910001429 cobalt ion Inorganic materials 0.000 claims description 2
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- RVPVRDXYQKGNMQ-UHFFFAOYSA-N lead(2+) Chemical compound [Pb+2] RVPVRDXYQKGNMQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 claims 1
- 229940063013 borate ion Drugs 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 229940085991 phosphate ion Drugs 0.000 claims 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 abstract description 10
- 235000010410 calcium alginate Nutrition 0.000 abstract description 9
- 239000000648 calcium alginate Substances 0.000 abstract description 9
- 229960002681 calcium alginate Drugs 0.000 abstract description 9
- 238000002803 maceration Methods 0.000 abstract description 4
- 238000007493 shaping process Methods 0.000 abstract description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract description 2
- 239000001110 calcium chloride Substances 0.000 abstract 1
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 1
- 230000005489 elastic deformation Effects 0.000 abstract 1
- 229940021013 electrolyte solution Drugs 0.000 description 11
- 239000004971 Cross linker Substances 0.000 description 9
- 239000003792 electrolyte Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229960005069 calcium Drugs 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 235000010413 sodium alginate Nutrition 0.000 description 6
- 239000000661 sodium alginate Substances 0.000 description 6
- 229940005550 sodium alginate Drugs 0.000 description 6
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 229910052712 strontium Inorganic materials 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 2
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003856 thermoforming Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001491705 Macrocystis pyrifera Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- HWGNBUXHKFFFIH-UHFFFAOYSA-I pentasodium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O HWGNBUXHKFFFIH-UHFFFAOYSA-I 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006298 saran Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- MPSJHIAGGNGGEZ-UHFFFAOYSA-K trisodium;2-(carboxylatomethoxy)butanedioate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)COC(C([O-])=O)CC([O-])=O MPSJHIAGGNGGEZ-UHFFFAOYSA-K 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000007666 vacuum forming Methods 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/043—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2300/00—Characterised by the use of unspecified polymers
- C08J2300/14—Water soluble or water swellable polymers, e.g. aqueous gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. (1)イオン架橋されたヒドロゲルを処理して、ヒドロゲルを所望の形状に保 持しながらかなりの量のイオン架橋をストリップし、そして (2)工程(1)の処理されたヒドロゲルを所望の形状に保持しながらヒドロゲ ルを再度イオン架橋することを特徴とする医療装置の製造方法。 2. 工程(1)の前記イオン架橋ヒドロゲルが管状前形状を有する請求の範囲第1 項に記載の方法。 3. 工程(1)の前記イオン架橋ヒドロゲルがアルギン酸バリウム又はアルギン酸 カルシウムから生成される請求の範囲第1項に記載の方法。 4. 前記再イオン架橋工程(2)がイオン架橋ヒドロゲルを水とカルシウムイオン 、ストロンチウムイオン、鉛イオン、銅イオン、アルミニウムイオン、鉄イオ ン、スズイオン、又はバリウムイオンを含む陽イオン架橋剤とを含む再架橋溶 液に暴露することを含む請求の範囲第3項に記載の方法。 5. 請求の範囲第4項に記載の方法により製造された医療装置。 6. (1)イオン架橋性ポリマーとイオン架橋剤とを含む組成物からヒドロゲルを 生成し、そして (2)(a)二次形状をヒドロゲルに付与し、 (b)二次形状を保持しながら、架橋のヒドロゲルをストリップし、そして (c)二次形状を保持しながら、ヒドロゲルを再度架橋することを含む工程 によりヒドロゲルを二次形状に成形することを特徴とする医療装置の製造方法 。 7. 工程(1)において、前記ヒドロゲルを管の長さに成形する請求の範囲第6項 に記載の方法。 8. 前記工程(2)(a)が前記ヒドロゲルを成形装置に取り付けることを含む請求の 範囲第7項に記載の方法。 9. 前記成形装置が少なくとも一つのコイル又はピグテールを管の長さ部分に形 成するための装置を含む請求の範囲第8項に記載の方法。 10.請求の範囲第9項に記載の方法により製造された医療装置。 11.前記ストリッピング工程(2)(b)が取り付けられたヒドロゲルを電解質溶液に 浸漬することを含む請求の範囲第6項に記載の方法。 12.前記電解質溶液が水と塩化カリウムとを含む請求の範囲第11項に記載の方法 。 13.塩化カリウムが約25重量%の濃度で電解質溶液中に存在する請求の範囲第12 項に記載の方法。 14.前記電解質溶液が可塑剤を更に含む請求の範囲第12項に記載の方法。 15.前記可塑剤が尿素、グリセロール、又はソルビトールである請求の範囲第14 項に記載の方法。 16.電解質溶液がほぼ室温である請求の範囲第11項に記載の方法。 17.電解質溶液をストリッピング工程(2)(b)中に攪拌する請求の範囲第11項に記 載の方法。 18.前記再架橋工程(2)(c)が取り付けられたヒドロゲルを水とイオン架橋剤とを 含む再架橋溶液に浸漬することを含む請求の範囲第8項に記載の方法。 19.ヒドロゲル組成物の前記ポリマーが陽イオン架橋性であり、かつ前記イオン 架橋剤がバリウムイオン、カルシウムイオン、マグネシウムイオン、ストロン チウムイオン、ホウ素イオン、ベリウムイオン、アルミニウムイオン、鉄イオ ン、銅イオン、コバルトイオン、鉛イオン、スズイオン、及び銀イオンからな る群から選ばれたイオンを含む請求の範囲第18項に記載の方法。 20.ヒドロゲル組成物の前記ポリマーが陰イオン架橋性であり、かつ前記イオン 架橋剤がリン酸イオン、クエン酸イオン、ホウ酸イオン、コハク酸イオン、マ レイン酸イオン、アジピン酸イオン、及びシュウ酸イオンからなる群から選ば れたイオンを含む請求の範囲第18項に記載の方法。 21.再架橋剤溶液が尿素、グリセロール、ソルビトール、防腐剤、抗生物質、又 は殺菌剤を更に含む請求の範囲第18項に記載の方法。 22.成形工程(2)をほぼ室温で行う請求の範囲第6項に記載の方法。 23.前記ポリマーが多糖である請求の範囲第6項に記載の方法。 24.前記多糖がアルギン酸、ペクチン酸、ヒアルロン酸、セルロース、キトサン 、キチン、澱粉、デキストラン、ヘパリン、コンドロイチン、陽イオングアー 、陽イオン澱粉、カルボキシメチルセルロース、カルボキシメチルキトサン、 カルボキシメチルデキストラン、カルボキシメチル澱粉、ヘパリンスルフェー ト、 及びコンドロイチンスルフェートからなる群から選ばれた員である請求の範囲 第23項に記載の方法。 25.前記多糖がアルギン酸、ペクチン酸、及びヒアルロン酸、並びにそれらの塩 からなる群から選ばれた員である請求の範囲第23項に記載の方法。 26.前記イオン架橋剤がバリウムイオン、カルシウムイオン、ストロンチウムイ オン、及び銅イオンからなる群から選ばれる請求の範囲第25項に記載の方法。 27.ヒドロゲル組成物が崩壊剤を更に含む請求の範囲第6項に記載の方法。 28.崩壊剤が無機硫酸塩、無機リン酸塩、及びマグネシウムイオンからなる群か ら選ばれる請求の範囲第27項に記載の方法。 29.前記ポリマーがアルギン酸又はその塩であり、かつ前記イオン架橋剤がバリ ウムイオン又はカルシウムイオンである請求の範囲第6項に記載の方法。 30.前記ストリッピング工程(2)(b)がヒドロゲルをその二次形状に保持しながら 塩化カリウム、塩化ナトリウム、又は塩化リチウムの電解質溶液に浸漬するこ とを含み、かつ前記再架橋工程(2)(c)がヒドロゲルをその二次形状に保持しな がら水とカルシウムイオン、ストロンチウムイオン、鉛イオン、銅イオン、ア ルミニウムイオン、鉄イオン、スズイオン、又はバリウムイオンを含む陽イオ ン架橋剤とを含む再架橋溶液に浸漬することを含む請求の範囲第29項に記載の 方法。 31.前記陽イオン架橋剤がカルシウムイオン又はバリウムイオンを含む請求の範 囲第30項に記載の方法。 32.請求の範囲第31項に記載の方法により製造された医療装置。 33.電解質溶液がその溶液の重量を基準として約25%の濃度の塩化カリウム、塩 化ナトリウム、又は塩化リチウムを有する請求の範囲第30項に記載の方法によ り製造された医療装置。 34.電解質溶液が塩化カリウムの水溶液である請求の範囲第30項に記載の方法に より製造された医療装置。 35.浸漬が室温で行われる請求の範囲第30項に記載の方法により製造された医療 装置。 36.保持特性を有する弾性変形可能なステントである請求の範囲第30項に記載の 方法により製造された医療装置。 37.ステント、カテーテル、カニューレ、プラグ、又はリストリクターである請 求の範囲第6項に記載の医療装置。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/639,071 US5718862A (en) | 1996-04-24 | 1996-04-24 | Secondary shaping of ionically crosslinked polymer compositions for medical devices |
US08/639,071 | 1996-04-24 | ||
PCT/US1997/004469 WO1997039788A1 (en) | 1996-04-24 | 1997-03-27 | Secondary shaping of ionically cross-linked polymer compositions for medical devices |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000510714A true JP2000510714A (ja) | 2000-08-22 |
JP2000510714A5 JP2000510714A5 (ja) | 2004-12-02 |
JP4116079B2 JP4116079B2 (ja) | 2008-07-09 |
Family
ID=24562610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53806097A Expired - Fee Related JP4116079B2 (ja) | 1996-04-24 | 1997-03-27 | 医療装置用のイオン架橋ポリマー組成物の二次成形 |
Country Status (5)
Country | Link |
---|---|
US (1) | US5718862A (ja) |
EP (1) | EP0904121B1 (ja) |
JP (1) | JP4116079B2 (ja) |
DE (1) | DE69717990T2 (ja) |
WO (1) | WO1997039788A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014187952A (ja) * | 2013-03-27 | 2014-10-06 | Kibun Foods Inc | 麺状食品の製造方法 |
WO2015045940A1 (ja) * | 2013-09-30 | 2015-04-02 | 日立造船株式会社 | 形状記憶性樹脂組成物 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2778081B1 (fr) * | 1998-04-29 | 2000-08-25 | Fabrice Thevenet | Implants de renfort pour sutures tissulaires |
DE19904785A1 (de) * | 1999-02-05 | 2000-08-10 | Ulrich Zimmermann | Verfahren zur Herstellung von stabilem Alginatmaterial |
US6122552A (en) * | 1999-03-03 | 2000-09-19 | Cardiac Pacemakers, Inc. | Insertion apparatus for left ventricular access lead |
US6645947B1 (en) * | 1999-05-20 | 2003-11-11 | Chitogenics, Inc. | Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
US7273497B2 (en) * | 1999-05-28 | 2007-09-25 | Anova Corp. | Methods for treating a defect in the annulus fibrosis |
US20060247665A1 (en) * | 1999-05-28 | 2006-11-02 | Ferree Bret A | Methods and apparatus for treating disc herniation and preventing the extrusion of interbody bone graft |
US20070038231A1 (en) | 1999-05-28 | 2007-02-15 | Ferree Bret A | Methods and apparatus for treating disc herniation and preventing the extrusion of interbody bone graft |
US6368346B1 (en) | 1999-06-03 | 2002-04-09 | American Medical Systems, Inc. | Bioresorbable stent |
US6719797B1 (en) | 1999-08-13 | 2004-04-13 | Bret A. Ferree | Nucleus augmentation with in situ formed hydrogels |
US6719804B2 (en) | 2001-04-02 | 2004-04-13 | Scimed Life Systems, Inc. | Medical stent and related methods |
US20020188342A1 (en) * | 2001-06-01 | 2002-12-12 | Rykhus Robert L. | Short-term bioresorbable stents |
US6620202B2 (en) * | 2001-10-16 | 2003-09-16 | Scimed Life Systems, Inc. | Medical stent with variable coil and related methods |
US8328877B2 (en) * | 2002-03-19 | 2012-12-11 | Boston Scientific Scimed, Inc. | Stent retention element and related methods |
ES2276065T3 (es) * | 2002-05-09 | 2007-06-16 | Hemoteq Gmbh | Compuestos y metodos para revestir superficies de una manera hemocompatible. |
US8425926B2 (en) * | 2003-07-16 | 2013-04-23 | Yongxing Qiu | Antimicrobial medical devices |
EP1626067A1 (en) * | 2004-08-10 | 2006-02-15 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Biodegradable ceramic-polymer composite |
US9051411B2 (en) | 2004-08-16 | 2015-06-09 | Lawrence Livermore National Security, Llc | Shape memory polymers |
US11820852B2 (en) | 2004-08-16 | 2023-11-21 | Lawrence Livermore National Security, Llc | Shape memory polymers |
US20080039931A1 (en) * | 2006-04-25 | 2008-02-14 | Surmodics, Inc. | Hydrophilic shape memory insertable medical articles |
US8834496B2 (en) | 2006-06-13 | 2014-09-16 | Bret A. Ferree | Soft tissue repair methods and apparatus |
US8764835B2 (en) * | 2006-06-13 | 2014-07-01 | Bret A. Ferree | Intervertebral disc treatment methods and apparatus |
US9232938B2 (en) | 2006-06-13 | 2016-01-12 | Anova Corp. | Method and apparatus for closing fissures in the annulus fibrosus |
US8821549B2 (en) | 2006-06-13 | 2014-09-02 | Anova Corporation | Methods and apparatus for anulus repair |
EP2109784B2 (en) * | 2007-01-31 | 2016-10-05 | Novartis AG | Antimicrobial medical devices including silver nanoparticles |
CN107033368A (zh) | 2009-11-09 | 2017-08-11 | 聚光灯技术合伙有限责任公司 | 碎裂水凝胶 |
CN106913902A (zh) | 2009-11-09 | 2017-07-04 | 聚光灯技术合伙有限责任公司 | 多糖基水凝胶 |
US11993673B2 (en) | 2010-05-06 | 2024-05-28 | Lawrence Livermore National Security, Llc | Shape memory polymers |
US8603236B2 (en) * | 2010-12-01 | 2013-12-10 | Mattel, Inc. | Play composition including crosslinkable binder |
EP3040118A1 (en) * | 2014-12-29 | 2016-07-06 | Galderma S.A. | Ether cross-linked chondroitin hydrogels and their use for soft tissue applications |
IT202000000322A1 (it) * | 2020-01-10 | 2021-07-10 | Univ Degli Studi Di Trieste | Metodo per il riciclo di materiali ottenuti tramite gelificazione |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1495381B2 (de) * | 1963-09-07 | 1971-06-24 | Czeskoslovenska akademie ved , Prag | Verfahren zur herstellung von kontaktlinsen oder kontakt linsenrohlingen aus quellfaehigen hydrogelen |
US3271496A (en) * | 1964-01-27 | 1966-09-06 | Amicon Corp | Method of shaping polyelectrolyte polymer |
US3608057A (en) * | 1967-10-03 | 1971-09-21 | Amicon Corp | Process for making contact lenses |
US4286341A (en) * | 1979-04-16 | 1981-09-01 | Iowa State University Research Foundation, Inc. | Vascular prosthesis and method of making the same |
US4902295A (en) * | 1985-08-26 | 1990-02-20 | Hana Biologics, Inc. | Transplantable artificial tissue |
US4997443A (en) * | 1985-08-26 | 1991-03-05 | Hana Biologics, Inc. | Transplantable artificial tissue and process |
JPH0696023B2 (ja) * | 1986-11-10 | 1994-11-30 | 宇部日東化成株式会社 | 人工血管およびその製造方法 |
JPH066601B2 (ja) * | 1987-10-29 | 1994-01-26 | 株式会社紀文 | ゲル又は固定化ゲルの製造法 |
US5085629A (en) * | 1988-10-06 | 1992-02-04 | Medical Engineering Corporation | Biodegradable stent |
US5057606A (en) * | 1989-01-24 | 1991-10-15 | Minnesota Mining And Manufacturing Company | Form-in-place polysaccharide gels |
GR920100122A (el) * | 1991-04-05 | 1993-03-16 | Ethicon Inc | Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως. |
JPH066601A (ja) * | 1992-06-19 | 1994-01-14 | Ricoh Co Ltd | 画像読取装置 |
US5531716A (en) * | 1993-09-29 | 1996-07-02 | Hercules Incorporated | Medical devices subject to triggered disintegration |
US5541304A (en) * | 1994-05-02 | 1996-07-30 | Hercules Incorporated | Crosslinked hydrogel compositions with improved mechanical performance |
US5531735A (en) * | 1994-09-27 | 1996-07-02 | Hercules Incorporated | Medical devices containing triggerable disintegration agents |
US5684051A (en) * | 1996-04-24 | 1997-11-04 | Hercules Incorporated | Medical devices with improved elastic response |
-
1996
- 1996-04-24 US US08/639,071 patent/US5718862A/en not_active Expired - Lifetime
-
1997
- 1997-03-27 EP EP97917555A patent/EP0904121B1/en not_active Expired - Lifetime
- 1997-03-27 DE DE69717990T patent/DE69717990T2/de not_active Expired - Lifetime
- 1997-03-27 JP JP53806097A patent/JP4116079B2/ja not_active Expired - Fee Related
- 1997-03-27 WO PCT/US1997/004469 patent/WO1997039788A1/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014187952A (ja) * | 2013-03-27 | 2014-10-06 | Kibun Foods Inc | 麺状食品の製造方法 |
WO2015045940A1 (ja) * | 2013-09-30 | 2015-04-02 | 日立造船株式会社 | 形状記憶性樹脂組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO1997039788A1 (en) | 1997-10-30 |
DE69717990T2 (de) | 2003-07-24 |
DE69717990D1 (de) | 2003-01-30 |
EP0904121B1 (en) | 2002-12-18 |
EP0904121A4 (ja) | 1999-03-31 |
US5718862A (en) | 1998-02-17 |
EP0904121A1 (en) | 1999-03-31 |
JP4116079B2 (ja) | 2008-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4116079B2 (ja) | 医療装置用のイオン架橋ポリマー組成物の二次成形 | |
US5820608A (en) | Method for in vivo chemically triggered disintegration of medical device | |
JP4331795B2 (ja) | 改良された弾性応答を有する医療装置 | |
US6060534A (en) | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties | |
EP0704222B1 (en) | In vivo degradable medical device, composition and method for its production and process for its decomposition | |
CA2261806C (en) | Medical devices containing in-situ generated medical compounds | |
CN108601865B (zh) | 高强度生物医学材料 | |
CA2252600C (en) | Secondary shaping of ionically cross-linked polymer compositions for medical devices | |
JP2664930B2 (ja) | 人工皮膚素材及びその製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040322 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040322 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080401 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080417 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110425 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110425 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |